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ABSTRACT
Cytomegalovirus (CMV) infection has been associated with the development of myocarditis in humans. Our
established mouse model for CMV myocarditis allows detailed investigation of the immunopathogenic mech-
anisms and therapies for cardiovascular disease. The type I interferons (IFN-a/b ) are part of the innate
immune response to CMV infections. Previously, we have reported that daily treatment with low doses of
murine IFN-a/b administered by the oral–mucosal route significantly reduces early virus replication of
murine CMV in the spleen and liver of infected mice. The oral–mucosal route provides an alternate deliv-
ery system to the current modes of IFN administration and is associated with fewer side effects. Since pro-
phylactic treatment with type 1 IFNs may result in both antiviral and immunomodulatory effects that may
lessen the development of disease, we wished to study the effect of IFN-a/b on the development of my-
ocarditis. Low-dose oral use of type I IFN (10 IU/day for 7 days prior to virus infection) did not abrogate
myocarditis but suppressed the inflammatory response in both the acute and chronic phase of the disease.
Furthermore, low-dose oral use of IFN was as effective at inhibiting myocarditis as a single injection of a
high dose of IFN (20,000 IU) on the day of virus infection. These findings indicate the need for evaluation
of low-dose use of oral IFN in the development of improved clinical therapies for the treatment of cardio-
vascular disease.
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THE CARDIO VASCULA R DISEA SE, M YO CA RD ITIS, is character-ized by inflam mation and necrosis of cardiac muscle. The
disease is associated with heart failure, arrhythm ia, and sudden
death. Myocarditis patients may have myocardial infarctions as-
sociated with severe chest pain, electrocardiograp hic changes,
and elevated serum levels of creatine kinase. (1) The disease may
be induced by a number of physical, chemical, and infectious
agents, including viruses. (2) Viral myocarditis has been linked
with the subsequent development of dilated cardiomyopathy , a
disease that accounts for approximately 25% of all heart fail-
ures in North America.(3,4)
Viruses associated with myocarditis include, picornaviruses,
orthom yxoviruses, and the herpesviruses. Human cytom egalo-
virus (CMV), a herpesvirus that is ubiquitous in human popu-
lations, is associated with seropositivity, often exceeding 50%
in adults of developed countries. Overt disease is rare in im-
munocompete nt individuals, but may follow blood transfusions
resulting in a number of clinical manifestations, including my-
ocarditis. (5) Active CMV infection is a common major compli-
cation in heart transplant recipients and patients with AIDS, re-
sulting in allograft rejection and cardiac dysfunction , respec-
tively. (6,7 ) Heart transplant recipients with a primary CMV in-
fection have a 46% incidence of developing myocarditis. (8)
Approxim ately 50–65% of patients with active myocarditi s
are positive for CMV DNA in heart tissues. (9 ) Importantl y,
myocardial damage post-CM V infection may persist in im-
munocom promised patients and lead to dilated cardiom yopa-
thy. (10 )
The strict host specificity of CMV has not allowed the de-
velopment of a direct animal model for human CMV infection.
However, murine cytomegaloviru s (MCMV) infection of mice
provides an excellent experim ental model because it closely re-
sembles human CMV in gene sequences, tissue tropism, and
pathological sequelae. We have demonstrated myocarditis in
various inbred strains of mice following sublethal infection with
MCMV.(11,12) An inflamm atory response is first observed in
the heart at days 5–7 post infection (p.i.) and persists until at
least day 100 p.i. The disease appears to be biphasic with an
acute and chronic stage in susceptible strains of mice. Inflam-
mation varies from focal lymphocytic infiltration to intense, dif-
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fuse infiltration with degenerative changes ranging from loss of
striations, vacuolation, to myofiber drop out. Host genetic fac-
tors affect the severity of MCMV-induced  myocarditis, how-
ever susceptibility does not correlate with the presence of viral
antigens in cardiac muscle.(12) Indeed, viral DNA and viral tran-
scripts for immediate early (ie1) genes, as detected by nested
PCR, persists out to day 70 in the hearts of both susceptible
and resistant mouse strains (Fairweather, Shellam, and Lawson,
unpublished data).
While the pathogenesis of viral myocarditis in humans is not
well understood, experimental infection models have increased
our understanding of the pathogenic mechanisms involved in
the disease. (2) Our previous research has suggested that
MCMV-induced myocarditis is immunopatho logical in nature.
MCMV-induced myocarditis is associated with the production
of autoantibodies to cardiac muscle and an inflammatory infil-
trate. We have shown that T cells play a critical role in MCMV-
induced myocarditis because athymic mice, in contrast to T cell-
competent mice, do not develop myocarditis. (13) Both CD4 1
and CD8 1 T cells are required for disease development (Fair-
weather, Lathbury, Allan, Scalzo, Shellam, and Lawson, un-
published data). CD4 1 T cells are clearly important for im-
munoglobulin G (IgG) production, and CD8 1 T cells may
mediate cardiac tissue injury. However, the pathogenic T cell
antigenic epitope(s) recognized in MCMV-induced myo-cardi-
tis remain to be elucidated. In contrast to T cells, we have found
that NK1.1 1 cells partially protect against acute myo-carditis
(Fairweather, Lathbury, Allan, Scalzo, Shellam, and Lawson,
unpublished data).
Our previous research has examined heart-reactive IgG an-
tibodies, which are produced early during MCMV infection,
peak at days 10–14 p.i., and persist into the late phase of myo-
carditis (days 28–100 p.i.). (14) The early humoral immune re-
sponse is directed against a number of heart proteins, includ-
ing the contractile proteins troponin, tropomyosin, and myosin,
whereas the late immune response is predom inantly directed
against the heavy chain of cardiac myosin.(14) We have also
found anti-myosin antibodies associated with myocarditis in
wild mice that have been naturally infected with MCMV.(15) In
addition, MCMV-neutralizing monoclonal antibodies cross-re-
act with cardiac myosin.(1 6) Therefore, autoimmunity to myosin
is a prominent feature of the immune response to MCMV in-
fection.
Absorption experim ents using myosin isoforms revealed that
there were differences, both in titer and isoform specificity of
anti-myosin antibodies, between mouse strains that are suscep-
tible or resistant to disease. Only mice susceptible to MCMV-
induced myocarditis (BALB/c) have a population of antibodies
specific for the cardiac isoform of myosin. Although contro-
versy exists as to the direct pathogenic role of antibodies re-
acting with internal antigens such as myosin,(17,1 8) such au-
toantibodies appear to play an immunopathog enic role in
MCMV-induced myocarditis. (19) We have found that passive
transfer of affinity-isolated anti-cardiac myosin antibodies, ob-
tained from late immune sera of MCMV-infected  BALB/c
mice, induced cellular inflammation and myocardial necrosis
in uninfected BALB/c mice. Our model suggests that some anti-
CMV antibodies, while highly protective against CMV infec-
tion, may also be capable of inducing autoim mune disease.
These cardiac myosin-reactive antibodies (predominantly
IgG2a) cross-react with MCMV polypeptides (50, 100, 200
KDa) and the S2 region of myosin, suggesting that molecular
mimicry between MCMV and cardiac myosin could contribute
to the development of MCMV-induced myocarditis. (19)
These findings taken together highlight the immunological
nature of this disease and provide a basis for the development
of immunomodulatory therapies. Our present study uses the
well-established  mouse model for CMV myocarditis to exam-
ine the antiviral and immunomodulatory roles of the type I IFNs
(IFN- a / b ) in myocarditis. Our previous studies demonstrated
the efficacy of low-dose orally administered IFN (LDOA IFN)
treatment for reduction of early virus replication in the spleen
and liver of MCMV-infected mice.(20,21 ) The oral–mucosal
route provides an alternate delivery system to the current modes
(system ic delivery) of IFN administration which are limited,
due to the production of neutralizing antibodies and may be as-
sociated with severe side effects. Treatment with type I IFNs
may result in both antiviral and immunomodulatory effects that
are less favourable for the developm ent of myocarditis. In par-
ticular, we have studied the effects of LDOA IFN treatment of
MCMV-infected mice for changes in both the severity and du-
ration of heart disease.
The therapeutic efficacy of LDOA IFN in the development
of myocarditis was examined in female adult BALB/c mice (6
weeks old) obtained from Animal Resources Centre (Murdoch,
Western Australia). Mice (5/group) were treated with either
saline (10 m l/mouse) or type I IFN- a / b (Lee Biomolecular  Inc.,
CA; 10 IU/mouse per day in 10 m l of saline) orally for 7 days
prior to intraperitoneal (i.p.) injection with MCMV (a sublethal
dose of 103 pfu/mouse diluted in 100 m l of pyrogen-free phos-
phate-buffered saline). A separate group of mice were injected
i.p. with 20,000 IU IFN-a / b 6 h prior to MCMV infection. The
MCMV stock (K181 strain) was prepared as a 20% salivary
gland homogenate from virus-infected weanling female
BALB/c mice and was titrated in mouse embryo fibroblasts by
plaque assay and expressed as pfu/ml as described previ-
ously. (22) Hearts from experimental mice were taken at day 6
and day 40 p.i., timepoints representing the acute and chronic
stage of myocarditis, transected along the midline, and
processed as paraffin embedded blocks. In previous experi-
ments, the average number of foci from serial sections was con-
sistent with the myocarditis score from a single level taken from
the interior myocardium (data not shown). Heart sections (two
sections cut per mouse with 5 mice/time point) were stained
with hematoxylin and eosin (H&E) and were examined histo-
logically for evidence of pathology (Table 1). Levels of signif-
icance were determined by the unpaired t-test assum ing unequal
variance between the means. Mice treated with LDOA IFN had
reduced inflammation in the hearts taken at both timepoints
(1.8-fold reduction, p # 0.03), indicating that LDOA IFN sup-
pressed the development of myocarditis. The high dose of IFN,
injected by the i.p. route, also reduced the severity of both acute
(1.6-fold reduction, p # 0.06) and chronic (3.6-fold reduction,
p # 0.00001) myocarditis.
To study the effect of LDOA IFN on myocarditis induced
by a 10-fold higher dose of virus, BALB/c mice were again
treated with either saline or IFN (LDOA and injected high dose)
similar to the above experiment but were infected with 104 pfu
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MCMV by the i.p. route. Hearts were examined for myocardi-
tis on days 7 and 35 p.i. Again, mice treated with IFN exhib-
ited less severe myocarditis than untreated mice (Table 2). The
inflammatory infiltrate of LDOA IFN-treated mice was often
more perivascular. Mice receiving LDOA IFN treatment or
20,000 IU IFN (i.p.) showed 1.5-fold reductions (p # 0.04) in
the number of inflammatory foci infiltrating the hearts at day
7 p.i. (Table 2). At day 35 p.i., mice treated with LDOA IFN
displayed a two-fold reduction (p # 0.0007) and mice injected
with 20,000 IU IFN showed a three-fold reduction (p #
0.00003) in myocarditis.
LDOA IFN treatm ent reduces MCMV titers in the spleen
and liver early in infection. (2 0,2 1) To assess further the effect
of IFN treatment on virus replication in the infected mice,
virus titers in the salivary gland, a site of persistence  for
MCMV, was quantitated  at day 7 p.i. for mice receiving 104
pfu MCMV and treated with or without IFN. This time point
was chosen because virus does not reach the salivary gland
until days 5–7 p.i., unlike virus replication  of the spleen and
liver, which is first observed at days 2–3 p.i. Individual sali-
vary glands were prepared and titrated in the plaque assay as
described previously .(22 ) Virus titers are expressed as mean
pfu/g tissue 6 standard error from 5 mice/group (Fig. 1). The
limit of detection of virus was 50 pfu/g tissue. No marked re-
duction in salivary gland virus titer was observed for mice
treated with LDOA IFN. However, mice injected with a high
dose of IFN on the day of virus infection showed significant
(p # 0.002) reduction in virus replication  in the salivary gland
at day 7 p.i. These findings suggest that LDOA IFN treatment
does not inhibit either the disseminat ion of virus to the sali-
vary glands or its replication at this distal site, 7 days fol-
lowing i.p. challenge with virus. Interesting ly, this result con-
trasts the suppression  of early replication of disseminat ed
MCMV in the liver and spleen observed in LDOA IFN-treated
mice at days 2–3 p.i. Therefore,  administration of IFN by the
oral route appears to have different effects on virus replica-
tion depending on the tissue site and/or the kinetics of virus
replication in organs. In contrast to the CD8 1 T cell-media ted
control of MCMV replication in the spleen and liver, (23 ) con-
trol of virus replication in the salivary glands is mediated by
CD4 1 T cells. (24) Thus, it is possible that LDOA IFN treat-
ment may have different effects on the stimulation of the
CD8 1 and CD4 1 T cell-m ediated antiviral immune responses.
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TA BL E 1. LDOA IFN- a / b RED UCES TH E
SEV ER ITY OF MCMV-IN DUCED MYO CA RD ITIS
Myocarditis a
Treatment Day 6b Day 40
Salinec 5.1 6  0.9 7.1 6  0.4
LDOA IFNd 2.8 6  0.6 3.8 6  0.5
20,000 IU IFNe 3.2 6  0.7 2.0 6  0.3
aMyocarditis was evaluated histologically as the average
number of inflam matory foci per heart section 6 standard er-
ror (two sections were examined from hearts transected through
the midline for individual mice from groups of 5 animals).
bMice were infected with 1 3 103 pfu MCMV by the i.p.
route and hearts examined histologically at the specified time
points.
cMice were treated orally with 10 m l of saline/mouse per day
for 1 week prior to virus infection.
dMice were treated orally with 10 IU MuIFN- a / b
(10 m l/mouse per day) for 1 week prior to virus infection.
eMice were injected with 20,000 IU MuIFN- a / b by the i.p.
route 6 h before virus infection.
TA BL E 2. LDOA IFN- a / b RED U CE S T HE SEV ERITY
OF MY OCARDITIS IN BALB/C MICE INFEC TED
W ITH AN INCREA SED DO SE OF MCMV
Myocarditis a
Treatment Day 7b Day 35
Salinec 10.5 6  1.4 6.5 6  0.4
LDOA IFNd 7.6 6  0.7 3.3 6  0.5
20,000 IU IFNe 7.2 6  1.1 2.2 6  0.4
aMyocarditis was evaluated histologically as the average
number of inflam matory foci per heart section 6 standard er-
ror (two sections were examined from hearts transected through
the midline for individual mice from groups of 5 animals).
bMice were infected with 1 3 104 pfu MCMV by the i.p.
route, and hearts were examined histologically at the specified
time points.
cMice were treated orally with 10 m l of saline/mouse per day
for 1 week prior to virus infection.
dMice were treated orally with 10 IU MuIFN- a /b (10 m l/mouse
per day) for 1 week prior to virus infection.
eMice were injected with 20,000 IU MuIFN- a / b by the i.p.
route 6 h before virus infection.
FIG. 1. Low-dose oral type I interferon (LDOA IFN) treat-
ment does not inhibit early virus dissemination and replication
in the salivary gland. Groups of 5 BALB/c mice were either
given doses of 10 IU of MuIFN- a / b (LDOA IFN) or saline
(PBS) by the oral mucosal route daily for 7 days prior to i.p.
inoculation with 104 pfu MCMV or injected with 20,000 IU
MuIFN- a / b (i.p. IFN) 6 h before virus infection. Mean virus
titers 6 standard errors (pfu/g tissue) are shown for mice at day
7 p.i.
It is unlikely that LDOA IFN treatment will prevent the es-
tablishmen t of persistence  of MCMV in the host, especially
the salivary gland, in which there is no evidence of reduction
of infectious virus replication.  However,  our previous studies
have shown that MCMV persistence  in the salivary gland and
low-level transcriptio n of MCMV in the heart does not cor-
relate with susceptibili ty to myocarditis (Fairweather, Shel-
lam, and Lawson, unpublished  data). Thus the antiviral effects
of the type I IFNs are not entirely responsible  for inhibition
of the induction of myocarditis.
LDOA type I IFN (10 IU/day for 7 days prior to virus in-
fection) did not completely abrogate myocarditis but suppressed
the inflammatory response in both the acute and chronic phases.
Furtherm ore, LDOA IFN was as effective at suppressing myo-
carditis as a single injection of a high dose of IFN (20,000 IU).
We propose that predominant immunomodulatory effects of
LDOA IFN treatment influence the development of myocardi-
tis following MCMV infection. LDOA IFN therapy may pro-
vide a safe alternative in the development of improved clinical
treatments of cardiovascular disease. This study provides sup-
port for further investigations into the efficacy of LDOA IFN
as therapy for cardiovascular disease. The timing and dosage
of IFN and the effects of IFN treatment on virus persistence in
the heart warrant examination. Furthermore, we have recently
shown that there are differential antiviral activities of individ-
ual IFN- a subtypes in vivo. (25,26) It may be necessary to treat
myocarditis patients with a particular subtype of IFN-a to
achieve optimal protection from disease. These investigations
will provide important information on prophylactic therapy for
the benefit of people at risk of developing cardiovascular dis-
ease.
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